Clinical Trial ProgressCDI-988 yields additional positive Phase 1 data.
Influenza Drug EfficacyCocrystal has announced that studies of its influenza drug, CC-42344, have shown efficacy against the new avian influenza strain H5N1.
Safety And TolerabilityCocrystal Pharma announced favorable safety and tolerability results at dosage levels of up to 800mg per day for 10 consecutive days from the multiple-ascending dose (MAD) portion of the ongoing Phase 1 study with its oral protease inhibitor CDI-988.
Vaccine DevelopmentThe binding site for CC-42344 was not changed and can block reproduction of the new strain, making it an effective vaccine against the virus.